According to international guidelines, surveillance for HCC should be performed in patients at risk for tumor development by means of ultrasound (US), with or without the measurement of serum alpha-fetoprotein (AFP) [8,9], while the Barcelona Clinic Liver Cancer (BCLC) staging system should be adopted for HCC prognostication and treatment allocation [8,9]. The gene discussed is AFP; the disease is neoplasm.